Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

SOPHIA ANTIPOLIS, France, February 26 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced its financial results for full year 2008 and provided an overview of the development and pre-commercialization activities for naproxcinod, its lead investigational drug for the treatment of the signs and symptoms of osteoarthritis (OA).

Michele Garufi, Chief Executive Officer of NicOx, commented: "We believe NicOx has entered 2009 in its strongest strategic position to date. We intend to use the excellent platform that we have developed over the last several years to transform NicOx into a self-sustainable biopharmaceutical company. Central to our ambition is to maximize the strategic and economic value of naproxcinod by signing the most appropriate commercial deal for this unique new product. Our intention is to retain select commercialization rights to naproxcinod to enable the creation of our own sales and marketing operations. Therefore, in parallel with our on-going discussions with potential naproxcinod partners, we are accelerating our search for marketed or late-stage clinical products for in-licensing or acquisition to leverage our future commercial infrastructure. We are confident we will achieve these key near term milestones, which should position NicOx to deliver sustainable profitability in the mid-term."

    Key highlights 2008:

    - Successful completion of the phase 3 clinical program for naproxcinod
      in OA patients, with all three studies (301, 302 and 303) achieving
      highly statistically significant results on all three co-primary
      efficacy endpoints (the WOMAC(TM) pain and function subscales and
      patients' overall rating of disease status).

    - Positive results on naproxcinod's blood pressure profile from a
      prospectively designed statistical analysis of the pooled Office Blood
      Pressure Measurement (OBPM) data from the phase 3 pro
'/>"/>
SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Fla. , Aug. 18, 2014 TNI ... biotechnology company pioneering the manufacturing and marketing of innovative ... that the Company is providing a second notice of ... In making the announcement, Noreen Griffin , ... you in advance for your participation in the Annual ...
(Date:8/18/2014)... 18, 2014 China is increasingly ... the clinical research industry. Clinicaltrial.gov statistics highlight the ... its aging population; a high increase in infectious ... densely populated pool of patients and a track ... positive points, China also presents challenges for the ...
(Date:8/16/2014)... 2014 Firms in the ... and advisory services to businesses, government bodies and ... services are highly diverse as operators assist a ... from geological and geophysical consulting services to risk ... past five years, the recovery of the Canadian ...
(Date:8/16/2014)... have found a way to make atomic-force microscope probes ... as small as the weight of an individual virus. ... National University (ANU), hinges on using laser beams to ... , "The level of sensitivity achieved after cooling is ... a large virus that is 100 billion times lighter ...
Breaking Biology Technology:TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3Laser makes microscopes way cooler 2
... 17, 2010 Shire plc (LSE: SHP,NASDAQ: SHPGY ), the ... Anne Minto OBE, have been appointed to the,Shire Board of Directors with ... ... Human,Genetics at the Life Sciences Institute, University of Michigan ; an,Investigator ...
... June 17, 2010 An independent study has revealed,that Irish ... and consistent than a leading group of,international hypertension experts. , ... Conducted by the ... numerous blood pressure readings taken over a,24-hour period (known as ,Ambulatory Blood ...
... 17 OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, ... develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt ... believed to play a significant role in the establishment, metastasis and ... , , ...
Cached Biology Technology:Shire plc Appoints Two New Board Directors 2Shire plc Appoints Two New Board Directors 3Shire plc Appoints Two New Board Directors 4Independent Study Reveals dabl System Leads the way in Accurate Cardiovascular Diagnosis 2Independent Study Reveals dabl System Leads the way in Accurate Cardiovascular Diagnosis 3OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 2OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 3OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 4OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics 5
(Date:8/20/2014)... few years, Virginia Tech,s Wu Feng has built upon ... the "Computing in the Cloud" program, and synergistically complemented ... award from the Air Force on "big computing" for ... the National Institutes of Health on "big data" for ... "parallel computing" aspects from each grant, he was able ...
(Date:8/20/2014)... Carolina State University researchers have developed methods for electronically ... the electrical signals moths use to control those muscles. ... remotely-controlled moths, or "biobots," for use in emergency response. ... whether we can control the movement of moths for ... says Dr. Alper Bozkurt, an assistant professor of electrical ...
(Date:8/19/2014)... To improve students, chances of completing introductory biology ... Houston (UH) implemented a comprehensive student success program, ... failure. , Through a grant from the ... of Biology and Biochemistry embarked on a pilot ... for non-majors and "Introductory Biology" for science majors. ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Research paves way for development of cyborg moth 'biobots' 2University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... Management ... Solutions, ... a leader in finger-based biometric,identification and wireless public safety, announced today ... a patent for the,company,s "Biometric Identification Network Security" method., This ...
... time thinking about beer, but a group of Rice ... They,re using genetic engineering to create beer that contains ... reduce cancer and heart disease in lab animals. ... Engineered Machine (iGEM) competition Nov. 8-9 in Cambridge, Mass. ...
... and Infectious Diseases (NAID), one of the National Institutes ... of Washington (UW) to use systems biology approaches to ... response networks that are induced or altered during the ... research program will be led by Dr. Michael Katze, ...
Cached Biology News:BIO-key(R) Granted Additional Patent for Biometric Security Solution 2BIO-key(R) Granted Additional Patent for Biometric Security Solution 3Better beer: College team creating anticancer brew 2Better beer: College team creating anticancer brew 3NIAID funds studies of how SARS and bird flu evade antiviral responses 2
... easy transformation of the budding yeast, Saccharoyces ... simply by mixing a plasmid DNA and ... No complicated steps, such as centrifugation or ... particularly well suited for high-throughput transformation of ...
... The STag Purification Kits enable rapid analytical ... fusion proteins produced from appropriate vectors. Sufficient ... to 1 mg target protein under native ... with S-protein Agarose, which specifically retains STag ...
Request Info...
... Epitope: aa 16-25 of human GSK3 alpha. ... Storage: Store vial at -20 C prior to opening. ... aliquot contents and freeze at -20 C or below. ... Other Sub-Family: not assigned-Other ...
Biology Products: